PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MaaT Pharma Developing gut microbiome therapies to improve survival for cancer patients.	France	MAAT
Mabion S.A. Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.	Poland	MAB
MACROGENICS INC Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.	United States of America	MGNX
MADRIGAL PHARMACEUTICALS, INC. Develops and delivers the first FDA-approved treatment for the liver disease MASH.	United States of America	MDGL
Magle Chemoswed Holding AB A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.	Sweden	MAGLE
Mainz BioMed N.V. Develops at-home diagnostic tests for the early detection of life-threatening cancers.	Germany	MYNZ
MANNKIND CORP Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.	United States of America	MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Provides nucleic acid products and biologics safety testing for new therapies and vaccines.	United States of America	MRVI
Marinomed Biotech AG Develops virus-blocking products & immunology therapies via proprietary technology platforms.	Austria	MARI
Marker Therapeutics, Inc. Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.	United States of America	MRKR